421 related articles for article (PubMed ID: 10581228)
1. Huntington's disease progression. PET and clinical observations.
Andrews TC; Weeks RA; Turjanski N; Gunn RN; Watkins LH; Sahakian B; Hodges JR; Rosser AE; Wood NW; Brooks DJ
Brain; 1999 Dec; 122 ( Pt 12)():2353-63. PubMed ID: 10581228
[TBL] [Abstract][Full Text] [Related]
2. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
3. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease.
Ginovart N; Lundin A; Farde L; Halldin C; Bäckman L; Swahn CG; Pauli S; Sedvall G
Brain; 1997 Mar; 120 ( Pt 3)():503-14. PubMed ID: 9126061
[TBL] [Abstract][Full Text] [Related]
4. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease.
Weeks RA; Piccini P; Harding AE; Brooks DJ
Ann Neurol; 1996 Jul; 40(1):49-54. PubMed ID: 8687191
[TBL] [Abstract][Full Text] [Related]
5. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.
Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; Dunnett SB; Piccini P
Brain; 2003 May; 126(Pt 5):1127-35. PubMed ID: 12690052
[TBL] [Abstract][Full Text] [Related]
6. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study.
Turjanski N; Weeks R; Dolan R; Harding AE; Brooks DJ
Brain; 1995 Jun; 118 ( Pt 3)():689-96. PubMed ID: 7600086
[TBL] [Abstract][Full Text] [Related]
7. Age-related changes of dopamine D1-like and D2-like receptor binding in the F344/N rat striatum revealed by positron emission tomography and in vitro receptor autoradiography.
Suzuki M; Hatano K; Sakiyama Y; Kawasumi Y; Kato T; Ito K
Synapse; 2001 Sep; 41(4):285-93. PubMed ID: 11494399
[TBL] [Abstract][Full Text] [Related]
8. Gradients of dopamine D1- and D2/3-binding sites in the basal ganglia of pig and monkey measured by PET.
Rosa-Neto P; Doudet DJ; Cumming P
Neuroimage; 2004 Jul; 22(3):1076-83. PubMed ID: 15219579
[TBL] [Abstract][Full Text] [Related]
9. The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease.
Lawrence AD; Weeks RA; Brooks DJ; Andrews TC; Watkins LH; Harding AE; Robbins TW; Sahakian BJ
Brain; 1998 Jul; 121 ( Pt 7)():1343-55. PubMed ID: 9679785
[TBL] [Abstract][Full Text] [Related]
10. Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease.
van Oostrom JC; Dekker M; Willemsen AT; de Jong BM; Roos RA; Leenders KL
Eur J Neurol; 2009 Feb; 16(2):226-31. PubMed ID: 19138335
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A2A receptor imaging with [11C]KF18446 PET in the rat brain after quinolinic acid lesion: comparison with the dopamine receptor imaging.
Ishiwata K; Ogi N; Hayakawa N; Oda K; Nagaoka T; Toyama H; Suzuki F; Endo K; Tanaka A; Senda M
Ann Nucl Med; 2002 Nov; 16(7):467-75. PubMed ID: 12508837
[TBL] [Abstract][Full Text] [Related]
12. The problem of antipsychotic treatment for functional imaging in Huntington's disease: receptor binding, gene expression and locomotor activity after sub-chronic administration and wash-out of haloperidol in the rat.
Besret L; Page KJ; Dunnett SB
Brain Res; 2000 Jan; 853(1):125-35. PubMed ID: 10627316
[TBL] [Abstract][Full Text] [Related]
13. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length.
Antonini A; Leenders KL; Eidelberg D
Ann Neurol; 1998 Feb; 43(2):253-5. PubMed ID: 9485067
[TBL] [Abstract][Full Text] [Related]
14. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease.
van Oostrom JC; Maguire RP; Verschuuren-Bemelmans CC; Veenma-van der Duin L; Pruim J; Roos RA; Leenders KL
Neurology; 2005 Sep; 65(6):941-3. PubMed ID: 16186542
[TBL] [Abstract][Full Text] [Related]
15. Thalamic metabolism and symptom onset in preclinical Huntington's disease.
Feigin A; Tang C; Ma Y; Mattis P; Zgaljardic D; Guttman M; Paulsen JS; Dhawan V; Eidelberg D
Brain; 2007 Nov; 130(Pt 11):2858-67. PubMed ID: 17893097
[TBL] [Abstract][Full Text] [Related]
16. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI
Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894
[TBL] [Abstract][Full Text] [Related]
17. Hypothalamic involvement in Huntington's disease: an in vivo PET study.
Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P
Brain; 2008 Nov; 131(Pt 11):2860-9. PubMed ID: 18829696
[TBL] [Abstract][Full Text] [Related]
18. Effect of amphetamine-induced dopamine release on radiotracer binding to D1 and D2 receptors in rat brain striatal slices.
Gifford AN; Park MH; Kash TL; Herman LM; Park EH; Gatley SJ; Volkow ND
Naunyn Schmiedebergs Arch Pharmacol; 2000 Nov; 362(4-5):413-8. PubMed ID: 11111836
[TBL] [Abstract][Full Text] [Related]
19. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain.
Seeman P; Niznik HB; Guan HC; Booth G; Ulpian C
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10156-60. PubMed ID: 2574862
[TBL] [Abstract][Full Text] [Related]
20. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers.
Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P
Neurobiol Dis; 2010 Feb; 37(2):356-61. PubMed ID: 19853661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
